Exploring the Benefits and Risks of Next-gen Weight Loss Drugs
WHO:
CBS News - More than 30 million people in the U.S. have benefited from GLP-1 medications.
statnews.com - Eli Lilly is the company behind the next-generation obesity drug retatrutide.
WHAT:
The Guardian - In a phase 3 trial, patients receiving weekly retatrutide injections for 40 weeks lost more than four times as much weight as those on placebo, with an average drop in long-term blood sugar (HbA1c) more than twice that of the placebo.
The Guardian - Participants on retatrutide lost on average about 11.5% to 15.3% of body weight, compared to 2.6% with the placebo.
The Guardian - Fourteen participants experienced serious adverse events during the trial, including two in the placebo group.
The Guardian - The trial involved 930 adults with type 2 diabetes who were randomly assigned to receive 4mg, 9mg, or 12mg of retatrutide, or placebo.
CBS News - GLP-1 drugs were approved 20 years ago for diabetes treatment and have been found to significantly reduce weight.
statnews.com - Eli Lilly's retatrutide led to rapid weight loss and helped people with diabetes lower blood sugar in a late-stage study called TRANSCEND-T2D-1.
statnews.com - In the study, seven out of 403 participants receiving retatrutide experienced arrhythmias, and three experienced major cardiovascular complications, compared to none in the placebo group.
WHERE:
statnews.com - Data on retatrutide was presented at the annual meeting of the American Diabetes Association.
WHEN:
statnews.com - New data on the safety and tolerability of retatrutide was disclosed on a Saturday.
WHY:
CBS News - Experts suggest GLP-1 drugs might be useful in treating other diseases associated with obesity, including cancer.
HOW:
The Guardian - The triple hormone drug mimics three gut hormones: GLP-1, GIP, and glucagon, which help control appetite, blood sugar, and metabolism.
statnews.com - The safety and tolerability data for retatrutide were published in the Lancet.
(UPDATED June 7, 2026 17:18 UTC)
In a significant phase 3 trial involving 930 adults with type 2 diabetes, patients receiving weekly injections of the triple hormone drug retatrutide for 40 weeks lost more than four times as much weight as those on a placebo, with an average weight loss of about 11.5% to 15.3%. Additionally, participants on retatrutide saw a long-term blood sugar drop that was more than twice that of the placebo group, although fourteen participants experienced serious adverse events during the trial, including two from the placebo group. This innovative drug mimics three gut hormones—GLP-1, GIP, and glucagon—that play crucial roles in controlling appetite, blood sugar, and metabolism.
--
(UPDATED June 7, 2026 15:20 UTC)
More than 30 million people in the U.S. have benefited from GLP-1 medications, which were originally approved two decades ago for diabetes treatment and have shown significant weight loss effects. Eli Lilly's next-generation obesity drug, retatrutide, demonstrated rapid weight loss and improved blood sugar levels in a late-stage study presented at the annual meeting of the American Diabetes Association, although it did raise concerns with some participants experiencing arrhythmias and major cardiovascular complications. Experts believe GLP-1 drugs could also be valuable in treating other obesity-related diseases, including cancer, with new safety and tolerability data for retatrutide published in the Lancet.